Abstract
High-mobility group box-1 (HMGB1) protein was originally described as a nuclear DNA-binding protein that functions as a structural cofactor critical for proper transcriptional regulation and gene expression. Recent studies indicate that damaged, necrotic cells liberate HMGB1 into the extracellular milieu where it functions as a proinflammatory cytokine. Indeed, HMGB1 represents a novel family of inflammatory cytokines composed of intracellular proteins that can be recognized by the innate immune system as a signal of tissue damage. Posttranslational modifications of HMGB1 determine its interactions with other proteins and modulate its biological activity. However, very little is known about how these posttranslational modifications of HMGB1 affect its extracellular inflammatory activity and pathological potential. These studies can provide more efficient therapeutic strategies directed against specific HMGB1 isoforms. Therapeutic strategies against these specific HMGB1 isoforms can serve as models for more efficient therapeutic strategies against rheumatoid arthritis or sepsis. This article reviews the recent studies on HMGB1 regulation and their impact on the inflammatory activity and pathological contribution of HMGB1 to infectious and inflammatory disorders.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ulloa, L. and Tracey, K. J. (2005) The “cytokine profile”: a code for sepsis. Trends Mol. Med. 11, 56–63.
Lotze, M. T. and Tracey, K. J. (2005) High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. Nat. Rev. Immunol. 5, 331–342.
Ulloa, L. (2005) The vagus nerve and the nicotinic anti-inflammatory pathway. Nat. Rev. Drug Disc. 4, 673–684.
Ulloa, L., Ochani, M., Yang, H., et al. (2002) Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation. PNAS 99, 12,351–12,356.
Messmer, D., Yang, H., Telusma, G., et al. (2004) High mobility group box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J. Immunol. 173, 307–313.
Yang, H., Ochani, M., Li, J., et al. (2004) Reversing established sepsis with antagonists of endogenous high-mobility group box 1. PNAS 101, 296–301.
Scaffidi, P., Misteli, T., and Bianchi, M. E. (2002) Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 418, 191–195.
Andersson, U., Wang, H., Palmblad, K., et al. (2000) High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J. Exp. Med. 192, 565–570.
Park, J. S., Arcaroli, J., Yum, H.-K., et al. (2003) Activation of gene expression in human neutrophils by high mobility group box 1 protein. Am. J. Physiol. Cell. Physiol. 284, C870–C879.
Li, J., Kokkola, R., Tabibzadeh, S., et al. (2003) Structural basis for the proinflammatory cytokine activity of high mobility group box 1. Mol. Med. 9, 37–45.
Degryse, B., Bonaldi, T., Scaffidi, P., et al. (2001) The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells. J. Cell Biol. 152, 1197–1206.
Cossu, G. and Bianco, P. (2003) Mesoangioblasts—vascular progenitors for extravascular mesodermal tissues. Curr. Opin. Genet. Dev. 13, 537–542.
Palumbo, R., Sampaolesi, M., De Marchis, F., et al. (2004) Extracellular HMGB1, a signal of tissue damage, induces mesoangioblast migration and proliferation. J. Cell Biol. 164, 441–449.
Bonaldi, T., Talamo, F., Scaffidi, P., et al. (2003) Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO 22, 5551–5560.
Gardella, S., Andrei, C., Ferrera, D., et al. (2002) The nuclear protein HMGB1 is secreted by monocytes via a non-classical, vesicle-mediated secretory pathway. EMBO Rep. 3, 995–1001.
Alexandrova, E. A. and Beltchev, B. G. (1988) Acetylated HMG1 protein interacts specifically with homologous DNA polymerase alpha in vitro. Biochem. Biophys. Res. Commun. 154, 91–927.
Dimov, S. I., Alexandrova, E. A., and Beltchev, B. G. (1990) Differences between some properties of acetylated and nonacetylated forms of HMG1 protein. Biochem. Biophys. Res. Commun. 166, 819–826.
Ugrinova, I., A, P. E., Armengaud, J., and Pashev, I. G. (2001) In vivo acetylation of HMG1 protein enhances its binding affinity to distorted DNA structures. Biochemistry 40, 14,655–14,660.
Li, J., Wang, H., Mason, J. M., et al. (2004) Recombinant HMGB1 with cytokine-stimulating activity. J. Immunol. Methods. 289, 211–223.
Zimmermann, K., Volkel, D., Pable, S., et al. (2004) Native versus recombinant high-mobility group B1 proteins: functional activity in vitro. Inflammation 28, 221–229.
Park, J. S., Svetkauskaite, D., He, Q., et al. (2004) Involvement of Toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J. Biol. Chem. 279, 7370–7377.
Akira, S. and Takeda, K. (2004) Toll-like receptor signalling. Nat. Rev. Immunol. 4, 499–511.
Wang, H., Bloom, O., Zhang, M., et al. (1999) HMG-1 as a late mediator of endotoxin lethality in mice. Science 285, 248–251.
Abraham, E., Arcaroli, J., Carmody, A., Wang, H., and Tracey, K. J. (2000) Cutting Edge: HMG-1 as a Mediator of Acute Lung Inflammation. J. Immunol. 165, 2950–2954.
Pullerits, R., Jonsson, I. M., Verdrengh, M., et al. (2003) High mobility group box chromosomal protein 1, a DNA binding cytokine, induces arthritis. Arthritis Rheum. 48, 1693–1700.
Dumitriu, I. E., Baruah, P., Valentinis, B., et al. (2005) Release of high mobility group box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J. Immunol. 174, 7506–7515.
Dumitriu, I. E., Baruah, P., Bianchi, M. E., Manfredi, A. A., and Rovere-Querini, P. (2005) Requirement of HMGB1 and RAGE for the maturation of human plasmacytoid dendritic cells. Eur. J. Immunol. 35, 2184–2190.
Fiuza, C., Bustin, M., Talwar, S., et al. (2003) Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood 101, 2652–2660.
Degryse, B. and Virgilio, M. (2003) The nuclear protein HMGB1, a new kind of chemokine? FEBS Lett. 553, 11–17.
Sappington, P. L., Yang, R., Yang, H., Tracey, K. J., Delude, R. L. and Fink, M. P. (2002). HMGB1 B box increases the permeability of Caco-2 enterocytic monolayers and impairs intestinal barrier function in mice. Gastroenterology 123, 790–802.
Rauvala, H. and Pihlaskari, R. (1987) Isolation and some characteristics of an adhesive factor of brain that enhances neurite outgrowth in central neurons. J. Biol. Chem. 262, 16,625–16,635.
Merenmies, J., Pihlaskari, R., Laitinen, J., Wartiovaara, J., and Rauvala, H. (1991) 30-kDa heparin-binding protein of brain (amphoterin) involved in neurite outgrowth. Amino acid sequence and localization in the filopodia of the advancing plasma membrane. J. Biol. Chem. 266, 16,722–16,729.
Parkkinen, J., Raulo, E., Merenmies, J., et al. (1993) Amphoterin, the 30-kDa protein in a family of HMG1-type polypeptides. Enhanced expression in transformed cells, leading edge localization, and interactions with plasminogen activation. J. Biol. Chem. 268, 19,726–19,738.
Kuniyasu, H., Oue, N., Wakikawa, A., et al. (2002) Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J. Pathol. 196, 163–170.
Yang, H., Wang, H., Czura, C. J., and Tracey, K. J. (2005) The cytokine activity of HMGB1. J. Leukoc. Biol. 78, 1–8.
Hori, O., Brett, J., Slattery, T., et al. (1995) The receptor for advanced glycation end products (RAGE) is a cellular binding site for amphoterin. J. Biol. Chem. 270, 25,752–25,761.
Huttunen, H. J. and Rauvala, H. (2004) Amphoterin as an extracellular regulator of cell motility: from discovery to disease. J. Intern. Med. 255, 351–366.
Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108, 949–955.
Kokkola, R., Andersson, A., Mullins, G., et al. (2005) RAGE is the major receptor for the proinflammatory activity of HMGB1 in rodent macrophages. Scand. J. Immunol. 61, 1–9.
Wang, H., Liao, H., Ochani, M., et al. (2004) Cholinergic agonists inhibit HMGB1 release and improve survival in experimental sepsis. Nat. Med. 10, 1216–1221.
Huttunen, H. J., Fages, C., Kuja-Panula, J., Ridley, A. J., and Rauvala, H. (2002) Receptor for advanced glycation end products-binding COOH-terminal motif of amphoterin inhibits invasive migration and metastasis. Cancer Res. 62, 4805–4811.
Hervio, L. S., Coombs, G. S., Bergstrom, R. C., Trivedi, K., Corey, D. R., and Madison, E. L. (2000) Negative selectivity and the evolution of protease cascades: the specificity of plasmin for peptide and protein substrates. Chem. Biol. 7, 443–453.
Li, M., Carpio, D. F., Zheng, Y., et al. (2001) An essential role of the NF-κB/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells. J. Immunol. 166, 7128–7135.
Dunne, A. and O’Neill, L. A. (2005) Adaptor usage and Toll-like receptor signaling specificity. FEBS Lett. 579, 3330–3335.
Rashid, A. J., O’Dowd, B. F., and George, S. R. (2004) Minireview: diversity and complexity of signaling through peptidergic G protein-coupled receptors. Endocrinology 145, 2645–2652.
Rios, C. D., Jordan, B. A., Gomes, I., and Devi, L. A. (2001) G-protein-coupled receptor dimerization: modulation of receptor function. Pharmacol Ther. 92, 71–87.
Mistry, A. R., Falciola, L., Monaco, L., et al. (1997) Recombinant HMG1 protein produced in Pichia pastoris: a nonviral gene delivery agent. Biotechniques 22, 718–729.
Bottger, M., Vogel, F., Platzer, M., Kiessling, U., Grade, K., and Strauss, M. (1988) Condensation of vector DNA by the chromosomal protein HMG1 results in efficient transfection. Biochim. Biophys. Acta. 950, 221–228.
Rubartelli, A. and Sitia, R. (1995) Entry of exogenous polypeptides into the nucleus of living cells: facts and speculations. Trends Cell Biol. 5, 409–412.
Dietz, G. P. and Bahr, M. (2004) Delivery of bioactive molecules into the cell: the Trojan horse approach. Mol. Cell. Neurosci. 27, 85–131.
Krieg, A. M. (2002) CPG Motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. 20, 709–760.
Ulloa, L., Batliwalla, F. M., Andersson, U., Gregersen, P. K., and Tracey, K. J. (2003) High mobility group box chromosomal protein 1 as a nuclear protein, cytokine, and potential therapeutic target in arthritis. Arthritis Rheum. 48, 876–881.
Parkkinen, J. and Rauvala, H. (1991) Interactions of plasminogen and tissue plasminogen activator (t-PA) with amphoterin. Enhancement of t-PA-catalyzed plasminogen activation by amphoterin. J. Biol. Chem. 266, 16,730–16,735.
Ramachandran, C., Yau, P., Bradbury, E., Shyamala, G., Yasuda, H., and Walsh, D. (1984) Phosphorylation of high-mobility-group proteins by the calcium-phospholipid-dependent protein kinase and the cyclic AMP-dependent protein kinase. J. Biol. Chem. 259, 13,495–13,503.
von Knethen, A., Tautenhahn, A., Link, H., Lindemann, D., and Brune, B. (2005) Activation-induced depletion of protein kinase Cα provokes desensitization of monocytes/macrophages in sepsis. J. Immunol. 174, 4960–4965.
Chen, L.-Y., Doerner, A., Lehmann, P. F., Huang, S., Zhong, G., and Pan, Z. K. (2005) A novel protein kinase C (PKCɛ) is required for fMet-Leu-Phe-induced activation of NF-κB in human peripheral blood monocytes. J. Biol. Chem. 280, 22,497–22,501.
Aksoy, E., Goldman, M., and Willems, F. (2004) Protein kinase C epsilon: a new target to control inflammation and immune-mediated disorders. Int. J. Biochem. Cell Biol. 36, 183–188.
Sterner, R., Vidali, G., and Allfrey, V. G. (1979) Studies of acetylation and deacetylation in high mobility group proteins. Identification of the sites of acetylation in HMG-1. J. Biol. Chem. 254, 11,577–11,583.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc.
About this protocol
Cite this protocol
Parrish, W., Ulloa, L. (2007). High-Mobility Group Box-1 Isoforms as Potential Therapeutic Targets in Sepsis. In: Sioud, M. (eds) Target Discovery and Validation Reviews and Protocols. Methods in Molecular Biology™, vol 361. Humana Press. https://doi.org/10.1385/1-59745-208-4:145
Download citation
DOI: https://doi.org/10.1385/1-59745-208-4:145
Publisher Name: Humana Press
Print ISBN: 978-1-58829-890-4
Online ISBN: 978-1-59745-208-3
eBook Packages: Springer Protocols